Liquidia (NASDAQ:LQDA) Price Target Raised to $65.00

Posted by Geri Gentry on Oct 15th, 2026

Liquidia (NASDAQ:LQDA – Get Free Report) had its price target lifted by research analysts at HC Wainwright from $58.00 to $65.00 in a note issued to investors on Thursday, Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price target would suggest a potential upside of 91.51% from the company’s current price.

Other analysts have also recently issued reports about the company. Piper Sandler set a $129.00 price objective on Liquidia in a research report on Friday, July 24th. Stephens set a $130.00 target price on Liquidia in a research report on Friday, July 24th. Zacks Research cut Liquidia from a “hold” rating to a “strong sell” rating in a research note on Tuesday, September 22nd. Weiss Ratings upgraded Liquidia from a “sell (d-)” rating to a “hold (c)” rating in a research report on Tuesday, September 22nd. Finally, Wells Fargo & Company upped their price target on Liquidia from $30.00 to $33.00 and gave the stock an “equal weight” rating in a research note on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $77.85.

Read Our Latest Stock Analysis on LQDA

Liquidia Stock Up 26.6%

Shares of Liquidia stock opened at $33.94 on Thursday. The company has a current ratio of 2.31, a quick ratio of 2.12 and a debt-to-equity ratio of 0.63. The company’s fifty day simple moving average is $62.30 and its two-hundred day simple moving average is $61.74. The company has a market cap of $3.04 billion, a P/E ratio of 24.77 and a beta of 0.61. Liquidia has a 12-month low of $21.94 and a 12-month high of $93.61.

Liquidia (NASDAQ:LQDA – Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported $0.74 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.02). Liquidia had a return on equity of 149.65% and a net margin of 30.74%. The company had revenue of $171.68 million during the quarter, compared to the consensus estimate of $168.48 million. During the same quarter last year, the company posted ($0.49) earnings per share. The firm’s revenue for the quarter was up 1842.1% compared to the same quarter last year. Research analysts anticipate that Liquidia will post 2.05 EPS for the current year.

Insider Buying and Selling

In other Liquidia news, insider Rajeev Saggar sold 9,218 shares of Liquidia stock in a transaction on Monday, October 12th. The stock was sold at an average price of $28.48, for a total transaction of $262,528.64. Following the completion of the transaction, the insider owned 126,368 shares in the company, valued at approximately $3,598,960.64. The trade was a 6.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Sarah Krepp sold 5,245 shares of the business’s stock in a transaction on Monday, October 12th. The stock was sold at an average price of $28.48, for a total value of $149,377.60. Following the completion of the sale, the insider directly owned 115,241 shares in the company, valued at $3,282,063.68. This trade represents a 4.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 745,194 shares of company stock worth $41,081,702 over the last three months. Corporate insiders own 25.60% of the company’s stock.

Hedge Funds Weigh In On Liquidia

A number of hedge funds have recently bought and sold shares of LQDA. Quantinno Capital Management LP increased its position in shares of Liquidia by 3.6% during the 1st quarter. Quantinno Capital Management LP now owns 17,165 shares of the company’s stock valued at $648,000 after purchasing an additional 589 shares during the last quarter. Arizona State Retirement System lifted its stake in shares of Liquidia by 5.4% in the 2nd quarter. Arizona State Retirement System now owns 17,627 shares of the company’s stock worth $1,405,000 after purchasing an additional 900 shares during the period. Swiss National Bank boosted its holdings in shares of Liquidia by 1.3% in the first quarter. Swiss National Bank now owns 120,400 shares of the company’s stock worth $4,544,000 after buying an additional 1,600 shares during the last quarter. Valmark Advisers Inc. boosted its holdings in shares of Liquidia by 10.2% in the first quarter. Valmark Advisers Inc. now owns 20,546 shares of the company’s stock worth $775,000 after buying an additional 1,905 shares during the last quarter. Finally, Globeflex Capital L P bought a new stake in Liquidia during the second quarter valued at approximately $175,000. Institutional investors own 64.54% of the company’s stock.

Key Stories Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

Positive Sentiment: Liquidia will retain the ability to commercialize YUTREPIA for pulmonary arterial hypertension (PAH), reassuring investors that the product can remain available without interruption. The settlement resolves patent, antitrust, trade-secret and contract disputes. Liquidia settlement announcement
Positive Sentiment: Preliminary third-quarter YUTREPIA sales reached $222.7 million, and Liquidia reported $396.1 million in cash and equivalents as of September 30. Management expects ongoing sales and existing cash to fund settlement payments and clinical development without needing additional financing.
Positive Sentiment: Analyst sentiment improved following the agreement. BTIG upgraded LQDA to “buy” with a $70 price target, while Lifesci Capital raised its rating to “outperform” with a $59 target. Needham maintained a “buy” rating despite reducing its target to $58.
Neutral Sentiment: Unusually high options activity accompanied the move, with traders purchasing 30,594 call contracts—more than double typical call volume—indicating increased speculative interest but not guaranteeing further gains.
Neutral Sentiment: Several executives sold shares under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested awards. Because the transactions were scheduled and insiders retained substantial holdings, they are a limited standalone signal, although broader insider activity remains heavily weighted toward sales. Liquidia insider trading report
Negative Sentiment: The settlement requires Liquidia to pay United Therapeutics a net $380.7 million through 2026 and 2027, substantially reducing its cash cushion and potentially limiting investments in growth and research.
Negative Sentiment: Liquidia agreed not to appeal a patent ruling and is removing the PH-ILD indication from YUTREPIA’s label. It also ended promotion of Treprostinil Injection, narrowing potential commercial opportunities. Investors are therefore weighing the removal of legal risk against the settlement’s large financial cost and reduced product scope. Zacks settlement analysis

About Liquidia

(Get Free Report)

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).